TY - JOUR
T1 - Prevalence of asthma and other allergic conditions in Colombia 2009-2010
T2 - a cross-sectional study
AU - Dennis, Rodolfo J.
AU - Caraballo, Luis
AU - García, Elizabeth
AU - Rojas, María X.
AU - Rondon, Martín A.
AU - Pérez, Adriana
AU - Aristizabal, Gustavo
AU - Peñaranda, Augusto
AU - Barragan, Ana M.
AU - Ahumada, Velky
AU - Jimenez, Silvia
N1 - Funding Information:
This work was made possible by funding from Colciencias grant 540–2008, and by unrestricted research grants from MSD, Astra-Zeneca, GlaxoSmithKline, and Sanofi-Aventis. Dr Pérez was supported by a research supplement [Grant 3R37CA057030-20S1] from NCI during the conduction of this study and by the Michael & Susan Dell Foundation [Grant 8075] during the writing of this manuscript. Neither Colciencias nor any of the other sponsors had any role in the conception, design, analysis, interpretation of data, drafting the article or approving the final manuscript version to be published. We are indebted to Angelica Prieto and Cristina Venegas for their unstinting work in many of the study procedures, to Laura Bellamy for data analysis assistance, to all schools principals, teachers, parents and subjects for donating their time for this study, and to Hector Restrepo, Epidemiologist, for his work in data base creation, management, and analysis. We also thank Alberto Jurado and Alba Y. Díaz for data collection and randomization.
PY - 2012/5/2
Y1 - 2012/5/2
N2 - Background: While it is suggested that the prevalence of asthma in developed countries may have stabilized, this is not clear in currently developing countries. Current available information for both adults and children simultaneously on the burden and impact of allergic conditions in Colombia and in many Latin American countries is limited. The objectives of this study were to estimate the prevalence for asthma, allergic rhinitis (AR), atopic eczema (AE), and atopy in six colombian cities; to quantify costs to the patient and her/his family; and to determine levels of Immunoglobulin E (IgE) in asthmatic and healthy subjects.Methods: We conducted a cross-sectional, population-based study in six cities during the academic year 2009-2010. We used a school-based design for subjects between 5-17 years old. We carried out a community-based strategy for subjects between 1-4 years old and adults between 18-59 years old. Serum samples for total and antigen-specific (IgE) levels were collected using a population-based, nested, case-control design.Results: We obtained information on 5978 subjects. The largest sample of subjects was collected in Bogotá (2392). The current prevalence of asthma symptoms was 12% (95% CI, 10.5-13.7), with 43% (95% CI, 36.3-49.2) reporting having required an emergency department visit or hospitalization in the past 12 months. Physician diagnosed asthma was 7% (95% CI, 6.1-8.0). The current prevalence of AR symptoms was 32% (95% CI, 29.5-33.9), and of AE symptoms was 14% (95% CI, 12.5-15.3). We collected blood samples from 855 subjects; 60.2% of asthmatics and 40.6% of controls could be classified as atopic.Conclusions: In Colombia, symptom prevalence for asthma, AR and AE, as well as levels of atopy, are substantial. Specifically for asthma, symptom severity and absence from work or study due to symptoms are important. These primary care sensitive conditions remain an unmet public health burden in developing countries such as Colombia.
AB - Background: While it is suggested that the prevalence of asthma in developed countries may have stabilized, this is not clear in currently developing countries. Current available information for both adults and children simultaneously on the burden and impact of allergic conditions in Colombia and in many Latin American countries is limited. The objectives of this study were to estimate the prevalence for asthma, allergic rhinitis (AR), atopic eczema (AE), and atopy in six colombian cities; to quantify costs to the patient and her/his family; and to determine levels of Immunoglobulin E (IgE) in asthmatic and healthy subjects.Methods: We conducted a cross-sectional, population-based study in six cities during the academic year 2009-2010. We used a school-based design for subjects between 5-17 years old. We carried out a community-based strategy for subjects between 1-4 years old and adults between 18-59 years old. Serum samples for total and antigen-specific (IgE) levels were collected using a population-based, nested, case-control design.Results: We obtained information on 5978 subjects. The largest sample of subjects was collected in Bogotá (2392). The current prevalence of asthma symptoms was 12% (95% CI, 10.5-13.7), with 43% (95% CI, 36.3-49.2) reporting having required an emergency department visit or hospitalization in the past 12 months. Physician diagnosed asthma was 7% (95% CI, 6.1-8.0). The current prevalence of AR symptoms was 32% (95% CI, 29.5-33.9), and of AE symptoms was 14% (95% CI, 12.5-15.3). We collected blood samples from 855 subjects; 60.2% of asthmatics and 40.6% of controls could be classified as atopic.Conclusions: In Colombia, symptom prevalence for asthma, AR and AE, as well as levels of atopy, are substantial. Specifically for asthma, symptom severity and absence from work or study due to symptoms are important. These primary care sensitive conditions remain an unmet public health burden in developing countries such as Colombia.
UR - http://www.scopus.com/inward/record.url?scp=84860318263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860318263&partnerID=8YFLogxK
U2 - 10.1186/1471-2466-12-17
DO - 10.1186/1471-2466-12-17
M3 - Research Article
C2 - 22551171
AN - SCOPUS:84860318263
SN - 1471-2466
VL - 12
JO - BMC Pulmonary Medicine
JF - BMC Pulmonary Medicine
M1 - 17
ER -
